Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects

Drs. Christopher M. Gallagher and Adam Brufsky discuss real-world evidence to expand knowledge of CDK4/6 inhibitor-related adverse effects in HR+/HER2- metastatic breast cancer treatment.
This video is part of a larger CE/CME Certified program entitled: RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer. You can receive free CME credit, view this video, and download slides from the presentation at www.mededonthego.com/Video/pr...